Anti-Human CXCL13 Recombinant Antibody (MAb 5261) (CAT#: TAB-106MZ)

Figure 1 Capture Epitope Competition ELISA results for MAb 5261, MAb 5080, and 3D2 binding to native human (17A) and native mouse (17B) CXCL13.

Each data point represents an average of duplicate measurements from one of at least three independent experiments. Curves were fitted using four-parameter sigmoidal curve fit (curves are shown on the graph; R2 = 0.99).

Figure 2 Capture Epitope Competition ELISA results for MAb 5261, MAb 5080, and 3D2 binding to native human (17A) and native mouse (17B) CXCL13.

Each data point represents an average of duplicate measurements from one of at least three independent experiments. Curves were fitted using four-parameter sigmoidal curve fit (curves are shown on the graph; R2 = 0.99).

Figure 3 Percent Inhibition of human pre-B-697-hCXCR5 (18 A) and human tonsillar cell (18B) migration by MAb 5261.

Data represent an average of triplicate measurements +/- SEM from one of at least three experiments. Curves were fitted using four-parameter sigmoidal curve fit (curves are shown on the graph; R2 = 0.98-0.99).

Figure 4 Percent Inhibition of SJL/J (19A) and C57Black/6 (19B) Splenocyte Migration by MAb 5261.

Data from representative experiments are shown as mean of duplicate measurements +/- SD.

Figure 5 Percent Inhibition of human CXCL 13 -mediated internalization of human CXCR5 receptor by MAb 5261 and Isotype Control.

Data are average of triplicate measurements from one of at least three independent experiments. Curve was fitted using four-parameter sigmoidal curve fit (curves are shown on the graph; R2 = 0.99).